Table 3.
Other Comorbidities Characteristics of the Study Participants
| Variable | Category | The 4-Item Morisky, Green, and Levine -Medication Assessment Questionnaire (MGL-MAG) | P value* | |||
|---|---|---|---|---|---|---|
| High Adherence (n= 296) | Moderate Adherence (n= 170) | Low Adherence (n= 40) | ||||
| N (%) | N (%) | N (%) | N (%) | |||
| Dyslipidemia | YES | 329 (65.0) | 206 (62.6) | 108 (32.8) | 15 (4.6) | <0.001 |
| NO | 177 (35.0) | 90 (50.8) | 62 (35.0) | 25 (14.1) | ||
| Rheumatoid Arthritis | YES | 62 (12.3) | 37 (59.7) | 21 (33.9) | 4 (6.5) | 0.902 |
| NO | 444 (87.7) | 259 (58.3) | 149 (33.6) | 36 (8.1) | ||
| Gout | YES | 53 (10.5) | 37 (69.8) | 15 (28.3) | 1 (1.9) | 0.106 |
| NO | 453 (89.5) | 259 (57.2) | 155 (34.2) | 39 (8.6) | ||
| Thyroid Dysfunction | YES | 51 (10.1) | 28 (54.9) | 19 (37.3) | 4 (7.8) | 0.893 |
| NO | 454 (89.7) | 267 (58.8) | 151 (33.3) | 36 (7.9) | ||
| Benign Prosthetic Hyperplasia (BPH) | YES | 46 (9.1) | 26 (56.5) | 18 (39.1) | 2 (4.3) | 0.521 |
| NO | 460 (90.9) | 270 (58.7) | 152 (33.0) | 38 (8.3) | ||
| Chronic Kidney Disease (CKD) | YES | 39 (7.7) | 21 (53.8) | 13 (33.3) | 5 (12.8) | 0.485 |
| NO | 467 (92.3) | 275 (58.9) | 157 (33.6) | 35 (7.5) | ||
| Asthma | YES | 36 (7.1) | 25 (69.4) | 8 (22.2) | 3 (8.3) | 0.318 |
| NO | 470 (92.9) | 271 (57.7) | 162 (34.5) | 37 (7.9) | ||
| Cancer | YES | 22 (4.3) | 18 (81.8) | 4 (18.2) | 0 (0.0) | 0.062 |
| NO | 484 (95.7) | 278 (57.4) | 166 (34.3) | 40 (8.3) | ||
| Chronic Obstructive Pulmonary Disorder (COPD) | YES | 13 (2.6) | 10 (76.9) | 1 (7.7) | 2 (15.4) | 0.112 |
| NO | 493 (97.4) | 286 (58.0) | 169 (34.3) | 38 (7.7) | ||
| Liver disease | YES | 10 (2.0) | 5 (50.0) | 2 (20.0) | 3 (30.0) | 0.031 |
| NO | 496 (98.0) | 291 (58.7) | 168 (33.9) | 37 (7.5) | ||
| Irritable Bowel Disease | YES | 9 (1.8) | 9 (100.0) | 0 (0.0) | 0 (0.0) | 0.039 |
| NO | 497 (98.2) | 287 (57.7) | 170 (34.2) | 40 (8.0) | ||
| Peptic Ulcer Disease (PUD) | YES | 8 (1.6) | 6 (75.0) | 1 (12.5) | 1 (12.5) | 0.434 |
| NO | 498 (98.4) | 290 (58.2) | 169 (33.9) | 39 (7.8) | ||
| CNS disorders** | YES | 8 (1.6) | 5 (62.5) | 2 (25.0) | 1 (12.5) | 0.812 |
| NO | 498 (98.4) | 291 (58.4) | 168 (33.7) | 39 (7.8) | ||
| Neuropathy | YES | 7 (1.4) | 5 (71.4) | 2 (28.6) | 0 (0.0) | 0.665 |
| NO | 499 (98.6) | 291 (58.3) | 168 (33.7) | 40 (8.0) | ||
| Glaucoma | YES | 3 (0.6) | 2 (66.7) | 1 (33.3) | 0 (0.0) | 0.873 |
| NO | 503 (99.4) | 294 (58.4) | 169 (33.6) | 40 (8.0) | ||
| Lymphoma | YES | 2 (0.4) | 2 (100.0) | 0 (0.0) | 0 (0.0) | 0.491 |
| NO | 504 (99.6) | 294 (58.3) | 170 (33.7) | 40 (7.9) | ||
| Leukemia | YES | 1 (0.2) | 1 (100.00) | 0 (0.0) | 0 (0.0) | 0.701 |
| NO | 505 (99.8) | 295 (58.4) | 170 (33.7) | 40 (7.9) | ||
| OTHERS*** | YES | 4 (0.8) | 2 (50.0) | 0 (0.0) | 0 (0.0) | 0.708 |
| NO | 502 (99.2) | 294 (58.6) | 168 (33.5) | 40 (8.0) | ||
| CCI | Mean (SD) Median (IQR) |
3.91 (1.00) 4 (3–4) |
3.95 (0.98) 4 (3–4) |
3.89 (1.07) 4 (3–4) |
3.77 (0.89) 4 (3–4) |
0.410 |
Notes: *Statistically significance was set at P <0.05. **CNS disorders: Parkinson disease, Alzheimer disease, Epilepsy, Depression. ***Other diseases: Urinary incontinence, Erectile dysfunction, Sleep apnea.
Abbreviation: CCI, Charlson Comorbidity Index.